In other post-treatment biopsies, we did not observe mutations that were detected in baseline biopsies, such as the SMAD4 alteration in patient 7, perhaps related to inadequate tumor sampling as suggested by the lower tumor purity of the post-treatment blood sample compared to the baseline blood sample (Fig. 3a, Supplementary Data 1). Here, SMAD4 is linked to neoplasm.